Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Xiao Wei, Jun Yu, Zhengkun Xu, Chun Wang, Yonggui Wu
Proton pump inhibitors are widely used in the treatment of various acid-related diseases and are among the most commonly used drugs. Studies estimate that 25-70% of proton pump inhibitors are prescribed for inappropriate treatments, doses, and indications, where the benefits of proton pump inhibitor use may be less than the risk of adverse drug reactions for many patients. Acute interstitial nephritis is an immune-mediated atypical kidney injury in the long-term use of proton pump inhibitors that causes problems for clinicians and patients...
July 2022: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
#22
Niloofar Nobakht, Ramy M Hanna, Mohammad Kamgar, John Sinclair, Lewis Simon, Sina Emami, Anthony Sisk, Anjay Rastogi
A 70-year-old female patient developed acute interstitial nephritis (AIN) after treatment with non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPI), and Bromhexine. Renal biopsy confirmed the diagnosis, and the patient was treated with oral prednisone. Careful attention to timing of acute kidney injury (AKI) is crucial to diagnosing AIN.
March 2022: Clinical Case Reports
#23
MULTICENTER STUDY
Shruti Gupta, Samuel A P Short, Meghan E Sise, Jason M Prosek, Sethu M Madhavan, Maria Jose Soler, Marlies Ostermann, Sandra M Herrmann, Ala Abudayyeh, Shuchi Anand, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Wei-Ting Chang, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Abhijat Kitchlu, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Mark Eijgelsheim, Harish Seethapathy, Meghan D Lee, Ian A Strohbehn, Dwight H Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Lucy Flanders, Busra Isik, Omar Mamlouk, Jamie S Lin, Pablo Garcia, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Els Wauters, Sunandana Chandra, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Deborah Schrag, Kenar D Jhaveri, Kerry L Reynolds, Frank B Cortazar, David E Leaf
BACKGROUND: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. METHODS: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI...
October 2021: Journal for Immunotherapy of Cancer
#24
JOURNAL ARTICLE
Koki Kato, Tomohiro Mizuno, Takenao Koseki, Yoshimasa Ito, Masakazu Hatano, Kazuo Takahashi, Shigeki Yamada, Naotake Tsuboi
BACKGROUND/AIM: Concomitant proton pump inhibitor (PPI) and immune checkpoint inhibitor (ICPI) were determined as risk factors of acute kidney injury. To identify the type of PPI associated with ICPI-induced nephritis, we used the Japanese Adverse Drug Event Report database. PATIENTS AND METHODS: ICPIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab) and PPIs (esomeprazole, omeprazole, vonoprazan, rabeprazole, and lansoprazole) were selected as suspected nephritis-inducing drugs...
September 2021: In Vivo
#25
REVIEW
Julie Belliere, Julien Mazieres, Nicolas Meyer, Leila Chebane, Fabien Despas
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. The breaking of peripheral tolerance and the emergence of auto- or drug-reactive T-cells are the main pathophysiological hypotheses to explain renal complications after ICI exposure. ICIs can induce a large spectrum of renal symptoms with variable severity (from isolated electrolyte disorders to dialysis-dependent acute kidney injury (AKI)) and presentation (acute tubule-interstitial nephritis in >90% of cases and a minority of glomerular diseases)...
June 30, 2021: Diagnostics
#26
COMPARATIVE STUDY
Meghan D Lee, Harish Seethapathy, Ian A Strohbehn, Sophia H Zhao, Genevieve M Boland, Riley Fadden, Ryan Sullivan, Kerry L Reynolds, Meghan E Sise
BACKGROUND: Current guidelines for treatment of immune checkpoint inhibitor (ICI)-induced nephritis are not evidence based and may lead to excess corticosteroid exposure. We aimed to compare a rapid corticosteroid taper to standard of care. METHODS: Retrospective cohort study in patients with ICI-induced nephritis comparing a rapid taper beginning with 60 mg/day prednisone and tapered to 10 mg within 3 weeks to a historical control group that began 60 mg/day tapered to 10 mg within 6 weeks (standard of care)...
April 2021: Journal for Immunotherapy of Cancer
#27
Christine M Jane, V Narayanan Unni, K Vinod Kumar, Nanda Kachare, Bipi Prasannan, Jojo K Pullockara
Drug induced acute interstitial nephritis is an idiosyncratic reaction following a drug exposure. The commonest drugs implicated are nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics and proton pump inhibitors. Renal cortical necrosis is a rare cause of acute kidney injury caused by severe and sustained vasoconstriction of small renal vessels. There is a change in the epidemiology of acute kidney injury especially in developing countries where drug induced acute kidney injury is becoming increasingly common...
2020: Indian Journal of Nephrology
#28
JOURNAL ARTICLE
Alexander J Friedman, Anna J Elseth, Joel R Brockmeyer
OBJECTIVE: Our goal was to compile the most recent and accurate data on the side effects of proton pump inhibitors (PPI). We also compared the efficacy of PPI to the efficacy of different surgical options for acid reflux control. BACKGROUND: Proton pump inhibitors are the primary therapy for chronic control of gastroesophageal reflux disease (GERD), but newer studies demonstrate deleterious side effects. Collating this information and contrasting it with surgical therapy for GERD provides evidence for possible practice changes in treatment...
January 2022: American Surgeon
#29
JOURNAL ARTICLE
Matthew Mulroy, Sanaz Ghafouri, Anthony Sisk, Antoni Ribas, Ray Goshtaseb, Grace Cherry, John Shen
Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with relapsed metastatic melanoma previously treated with pembrolizumab who developed grade 3 immune-related renal toxicity after reintroduction of the same ICI, secondary to acute interstitial nephritis with accompanying high PR3-antineutrophil cytoplasmic antibody titer...
March 2021: Immunotherapy
#30
JOURNAL ARTICLE
Thiruvinvamalai S Dharmarajan
Proton pump inhibitors (PPIs) are proven medications of choice for gastroesophageal reflux disease (GERD), acid-related disorders, erosive esophagitis, Barrett esophagus, prevention of gastrointestinal bleeding while on nonsteroidal anti-inflammatory drugs, eosinophilic esophagitis, peptic ulcer disease, stress ulcer prophylaxis in critically ill patients, and other indications. Best practice guidelines from several sources on the appropriate indications and duration of PPI therapy have been summarized for easy assimilation...
January 2021: Journal of the American Medical Directors Association
#31
JOURNAL ARTICLE
Harish Seethapathy, Sophia Zhao, Ian A Strohbehn, Meghan Lee, Donald F Chute, Halla Bates, Gabriel E Molina, Leyre Zubiri, Shruti Gupta, Shveta Motwani, David E Leaf, Ryan J Sullivan, Osama Rahma, Kimberly G Blumenthal, Alexandra-Chloe Villani, Kerry L Reynolds, Meghan E Sise
BACKGROUND: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 receptor (PD-1). Being the more recently approved class of checkpoint inhibitors, there are no studies investigating the frequency, etiology and predictors of acute kidney injury (AKI) in patients receiving PD-L1 inhibitors...
October 2020: KI Reports
#32
JOURNAL ARTICLE
Subhankar Samal, Namrata Singhania, Saurabh Bansal, Girish Singhania
Several antibiotics, proton pump inhibitors, and nonsteroidal anti-inflammatory drugs can cause acute interstitial nephritis. This is not dose-dependent, and recurrence can occur with a second exposure of the same drug. Stopping the culprit is critical for successful management.
October 2020: Clinical Case Reports
#33
JOURNAL ARTICLE
Claire Stein, Stéphane Burtey, Julien Mancini, Marion Pelletier, Marion Sallée, Philippe Brunet, Philippe Berbis, Jean Jacques Grob, Stéphane Honoré, Caroline Gaudy, Noémie Jourde-Chiche
BACKGROUND: Immune checkpoints inhibitors have transformed the prognosis of advanced melanoma but are associated with immune-related adverse events (irAEs). We evaluated the incidence, risk factors and causes of acute kidney injury (AKI) in a monocentric real-life cohort of patients treated with anti-programmed death receptor-1 (anti-PD1) antibodies for advanced melanoma. METHODS: Retrospective collection of medical charts and comprehensive analysis of lab results from patients treated with nivolumab or pembrolizumab for advanced melanoma between 2014 and 2018 was carried out...
August 27, 2021: Nephrology, Dialysis, Transplantation
#34
JOURNAL ARTICLE
Gaurav Taneja, Punniyakoti V Thanikachalam, Satyendra K Rajput
Proton pump inhibitors (PPIs) have wide pleiotropic action in addition to their therapeutic potential in gastroesophageal reflux diseases. Conversely, recent reports revealed a significant incidence of toxic events of PPIs including nephritis, osteoporosis, and cardiac damage. Thus, the study was designed to reconcile the deceptive contraindications. The present investigation targeted to reveal the toxic impact of sub-acute and sub-chronic administration of pantoprazole (PPZ) with different concentrations (low dose 4 mg/kg, medium-dose 8 mg/kg and high dose 16 mg/kg once a day) on normal vascular endothelium and renal tissue of rats...
October 15, 2020: Toxicology Letters
#35
REVIEW
Maria Luísa Cordeiro Santos, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Anelise Costa Dos Santos Botelho, Fabrício Freire de Melo
Anticancer drug nephrotoxicity is an important and increasing adverse drug event that limits the efficacy of cancer treatment. The kidney is an important elimination pathway for many antineoplastic drugs and their metabolites, which occurs by glomerular filtration and tubular secretion. Chemotherapeutic agents, both conventional cytotoxic agents and molecularly targeted agents, can affect any segment of the nephron including its microvasculature, leading to many clinical manifestations such as proteinuria, hypertension, electrolyte disturbances, glomerulopathy, acute and chronic interstitial nephritis, acute kidney injury and at times chronic kidney disease...
April 24, 2020: World Journal of Clinical Oncology
#36
Neetu Sharma, Randy Ip, Tarik Hadid
Proton pump inhibitors (PPI)-induced acute interstitial nephritis and autoimmune hemolytic anemia can occur concomitantly, which should prompt discontinuation of PPI. PPI should wisely be prescribed and discontinued when no longer needed.
February 2020: Clinical Case Reports
#37
JOURNAL ARTICLE
Miguel Fontecha-Barriuso, Diego Martín-Sanchez, Julio M Martinez-Moreno, Daniela Cardenas-Villacres, Susana Carrasco, Maria D Sanchez-Niño, Marta Ruiz-Ortega, Alberto Ortiz, Ana B Sanz
Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux disease, has been associated to chronic kidney disease and acute interstitial nephritis. However, whether omeprazole is toxic to renal cells is unknown. Omeprazole has a lethal effect over some cancer cells, and cell death is a key process in kidney disease. Thus, we evaluated the potential lethal effect of omeprazole over tubular cells. Omeprazole induced dose-dependent cell death in human and murine proximal tubular cell lines and in human primary proximal tubular cell cultures...
May 2020: Redox Biology
#38
MULTICENTER STUDY
Frank B Cortazar, Zoe A Kibbelaar, Ilya G Glezerman, Ala Abudayyeh, Omar Mamlouk, Shveta S Motwani, Naoka Murakami, Sandra M Herrmann, Sandhya Manohar, Anushree C Shirali, Abhijat Kitchlu, Shayan Shirazian, Amer Assal, Anitha Vijayan, Amanda DeMauro Renaghan, David I Ortiz-Melo, Sunil Rangarajan, A Bilal Malik, Jonathan J Hogan, Alex R Dinh, Daniel Sanghoon Shin, Kristen A Marrone, Zain Mithani, Douglas B Johnson, Afrooz Hosseini, Deekchha Uprety, Shreyak Sharma, Shruti Gupta, Kerry L Reynolds, Meghan E Sise, David E Leaf
BACKGROUND: Despite increasing recognition of the importance of immune checkpoint inhibitor-associated AKI, data on this complication of immunotherapy are sparse. METHODS: We conducted a multicenter study of 138 patients with immune checkpoint inhibitor-associated AKI, defined as a ≥2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI...
February 2020: Journal of the American Society of Nephrology: JASN
#39
JOURNAL ARTICLE
Harish Seethapathy, Sophia Zhao, Donald F Chute, Leyre Zubiri, Yaa Oppong, Ian Strohbehn, Frank B Cortazar, David E Leaf, Meghan J Mooradian, Alexandra-Chloé Villani, Ryan J Sullivan, Kerry Reynolds, Meghan E Sise
BACKGROUND AND OBJECTIVES: Immune checkpoint inhibitor use in oncology is increasing rapidly. We sought to determine the frequency, severity, cause, and predictors of AKI in a real-world population receiving checkpoint inhibitors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included all patients who received checkpoint inhibitor therapy from May 2011 to December 2016 at Massachusetts General Hospital. Baseline serum creatinine, averaged 6 months before checkpoint inhibitor start date, was compared with all subsequent creatinine values within 12 months of starting therapy...
December 6, 2019: Clinical Journal of the American Society of Nephrology: CJASN
#40
REVIEW
Ziyad Al-Aly, Geetha Maddukuri, Yan Xie
Proton pump inhibitors (PPIs), long thought to be safe, are associated with a number of nonkidney adverse health outcomes and several untoward kidney outcomes, including hypomagnesemia, acute kidney injury, acute interstitial nephritis, incident chronic kidney disease, kidney disease progression, kidney failure, and increased risk for all-cause mortality and mortality due to chronic kidney disease. PPIs are abundantly prescribed, rarely deprescribed, and frequently purchased over the counter. They are frequently used without medical indication, and when medically indicated, they are often used for much longer than needed...
April 2020: American Journal of Kidney Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
